Colgate-Palmolive (NYSE:CL – Get Rating) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Sunday.
A number of other equities analysts have also issued reports on CL. Barclays lowered their target price on shares of Colgate-Palmolive from $80.00 to $77.00 and set an “equal weight” rating on the stock in a research report on Tuesday, January 31st. UBS Group increased their price target on Colgate-Palmolive from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Wednesday, March 29th. Royal Bank of Canada increased their price target on Colgate-Palmolive from $82.00 to $83.00 in a report on Monday, May 1st. Morgan Stanley raised Colgate-Palmolive from an “equal weight” rating to an “overweight” rating and set a $82.00 price target for the company in a report on Monday, January 30th. Finally, Wells Fargo & Company increased their price target on Colgate-Palmolive from $76.00 to $81.00 in a report on Monday, May 1st. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Colgate-Palmolive has a consensus rating of “Moderate Buy” and an average target price of $84.75.
Colgate-Palmolive Stock Down 0.1 %
CL stock opened at $76.21 on Friday. The company’s 50 day moving average price is $77.18 and its 200 day moving average price is $76.25. The company has a debt-to-equity ratio of 20.87, a quick ratio of 0.76 and a current ratio of 1.23. Colgate-Palmolive has a fifty-two week low of $67.84 and a fifty-two week high of $83.81. The firm has a market capitalization of $63.22 billion, a price-to-earnings ratio of 39.69, a PEG ratio of 3.91 and a beta of 0.49.
Colgate-Palmolive (NYSE:CL – Get Rating) last announced its quarterly earnings results on Friday, April 28th. The company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.70 by $0.03. The company had revenue of $4.77 billion for the quarter, compared to analyst estimates of $4.58 billion. Colgate-Palmolive had a net margin of 8.71% and a return on equity of 348.63%. The firm’s revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.74 earnings per share. On average, equities research analysts anticipate that Colgate-Palmolive will post 3.14 EPS for the current fiscal year.
Insider Activity
In related news, insider Jennifer Daniels sold 24,703 shares of the company’s stock in a transaction on Friday, May 19th. The stock was sold at an average price of $79.70, for a total transaction of $1,968,829.10. Following the completion of the transaction, the insider now directly owns 52,769 shares in the company, valued at approximately $4,205,689.30. The sale was disclosed in a document filed with the SEC, which is available through this link. In related news, insider Prabha Parameswaran sold 64,373 shares of Colgate-Palmolive stock in a transaction dated Monday, May 8th. The stock was sold at an average price of $80.58, for a total transaction of $5,187,176.34. Following the transaction, the insider now directly owns 12,427 shares of the company’s stock, valued at $1,001,367.66. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Jennifer Daniels sold 24,703 shares of Colgate-Palmolive stock in a transaction dated Friday, May 19th. The stock was sold at an average price of $79.70, for a total value of $1,968,829.10. Following the completion of the transaction, the insider now directly owns 52,769 shares in the company, valued at approximately $4,205,689.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 187,748 shares of company stock worth $15,138,660. 0.34% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Colgate-Palmolive
Several institutional investors and hedge funds have recently bought and sold shares of the business. Beaumont Financial Advisors LLC increased its holdings in Colgate-Palmolive by 2.7% during the first quarter. Beaumont Financial Advisors LLC now owns 4,842 shares of the company’s stock valued at $364,000 after buying an additional 127 shares during the period. NorthRock Partners LLC boosted its stake in Colgate-Palmolive by 4.7% in the first quarter. NorthRock Partners LLC now owns 2,824 shares of the company’s stock valued at $212,000 after acquiring an additional 128 shares in the last quarter. Equitable Holdings Inc. boosted its stake in Colgate-Palmolive by 1.7% in the third quarter. Equitable Holdings Inc. now owns 7,780 shares of the company’s stock valued at $547,000 after acquiring an additional 133 shares in the last quarter. Rowland & Co. Investment Counsel ADV boosted its stake in Colgate-Palmolive by 3.7% in the first quarter. Rowland & Co. Investment Counsel ADV now owns 3,695 shares of the company’s stock valued at $278,000 after acquiring an additional 133 shares in the last quarter. Finally, Gladstone Institutional Advisory LLC boosted its stake in Colgate-Palmolive by 2.1% in the first quarter. Gladstone Institutional Advisory LLC now owns 6,329 shares of the company’s stock valued at $476,000 after acquiring an additional 133 shares in the last quarter. Hedge funds and other institutional investors own 77.63% of the company’s stock.
Colgate-Palmolive Company Profile
(Get Rating)
Colgate-Palmolive Co is engaged in the manufacturing and distribution of consumer products. It operates through the Oral, Personal and Home Care, and Pet Nutrition segments. The Oral, Personal and Home Care segment represents North America, Latin America, Europe, Asia Pacific, and Africa or Eurasia, all of which sell to a variety of retail and wholesale customers and distributors.
Further Reading
Receive News & Ratings for Colgate-Palmolive Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Colgate-Palmolive and related companies with MarketBeat.com’s FREE daily email newsletter.